<DOC>
	<DOCNO>NCT00388518</DOCNO>
	<brief_summary>This 6 arm study ass efficacy , safety , tolerability pharmacokinetics aleglitazar therapy patient Type 2 diabetes . Patients randomise one 6 treatment arm , receive one 4 dos aleglitazar , Actos open-label active comparator , placebo . Aleglitazar administer start dose 0.05mg po daily , Actos administer dose 45mg daily . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Aleglitazar Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes , diagnose &gt; =1 month screening ; either drugnaive , pretreated maximum 2 oral antihyperglycemic agent submaximal dos ; HbA1c &lt; =10.0 % screening , 7.010.0 % prerandomisation visit . type 1 diabetes ; currently previously treat insulin , thiazolidinedione , dual Peroxisome Proliferator Activated Receptor ( PPAR ) agonist ; clinically significant cardiovascular disease ; Congestive Heart Failure ( CHF ) New York Heart Association ( NYHA ) 34 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>